News Article | June 17, 2015
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/n8gnwf/substance_drug) has announced the addition of the "Substance (Drug) Abuse - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Substance (Drug) Abuse, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Substance (Drug) Abuse and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
News Article | June 23, 2015
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/rpgm26/dystonia) has announced the addition of the "Dystonia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Dystonia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dystonia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
News Article | May 28, 2015
The report “Dystonia – Pipeline Review, H1 2015” provides comprehensive information on the therapeutic development for Dystonia. Dystonia is characterized by persistent or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both. Dystonia affects men, women, and children of all ages and backgrounds. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report on H1 2015 pipeline review of Dystonia with 19 market data tables and 13 figures, spread across 48 pages is available at http://www.rnrmarketresearch.com/dystonia-pipeline-review-h1-2015-market-report.html . Companies discussed in this Dystonia – Pipeline Review, H1 2015 report include Addex Therapeutics Ltd, Advicenne Pharma, EpiVax, Inc., Ipsen S.A., Medy-Tox Inc. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Drug Profiles mentioned in this report are abobotulinumtoxin A, abobotulinumtoxin A next generation, ADV-6979, dipraglurant ER, dipraglurant IR, onabotulinumtoxin A, onabotulinumtoxin A. Featured News & Press Releases cover by this report includes: Jan 19, 2015: Addex and Dystonia Medical Research Foundation Announce Partnership to Explore the Therapeutic use of Dipraglurant in the Treatment of Dystonia; Apr 04, 2014: Medytox Meditoxin(Neuronox) registered in 27 countries worldwide; Feb 05, 2014: Ipsen announces clinical results of Dysport Next Generation and its intent to file the first ready-to-use liquid toxin A in Europe and ROW; Sep 04, 2013: Chronic treatment with Addex Dipraglurant Rescues Impairment of Long-Term Synaptic Plasticity in a Validated Preclinical Model of Primary Generalized Torsion Dystonia 1; Apr 22, 2013: Addex Obtains European Composition Of Matter Patent Covering Dipraglurant And Other mGlu5 Negative Allosteric Modulators; Apr 18, 2013: Addex's Dipraglurant Normalizes Striatal Cholinergic Dysfunction In Validated Preclinical Model Of Primary Generalized Torsion Dystonia 1; Jan 29, 2013: Addex Therapeutics's Dipraglurant Reduces Motor Abnormalities In Preclinical Model Of Dystonia; Feb 26, 2007: Epivax Funded To Advance Research On A New, Improved "Botox". Order a purchase copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=386034 . (This is a premium report priced at US$2000 for a single user License.) List of Tables Number of Products under Development for Dystonia, H1 2015 7 Number of Products under Development for Dystonia - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Late Stage Development, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Dystonia - Pipeline by Addex Therapeutics Ltd, H1 2015 14 Dystonia - Pipeline by Advicenne Pharma, H1 2015 15 Dystonia - Pipeline by EpiVax, Inc., H1 2015 16 Dystonia - Pipeline by Ipsen S.A., H1 2015 17 Dystonia - Pipeline by Medy-Tox Inc., H1 2015 18 Assessment by Monotherapy Products, H1 2015 19 Number of Products by Stage and Target, H1 2015 21 Number of Products by Stage and Mechanism of Action, H1 2015 23 Number of Products by Stage and Route of Administration, H1 2015 25 Number of Products by Stage and Molecule Type, H1 2015 27 Dystonia Therapeutics - Recent Pipeline Updates, H1 2015 36 Dystonia - Dormant Projects, H1 2015 40 List of Figures Number of Products under Development for Dystonia, H1 2015 7 Number of Products under Development for Dystonia - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Comparative Analysis by Clinical Stage Development, H1 2015 11 Assessment by Monotherapy Products, H1 2015 19 Number of Products by Top 10 Targets, H1 2015 20 Number of Products by Stage and Top 10 Targets, H1 2015 21 Number of Products by Top 10 Mechanism of Actions, H1 2015 22 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 23 Number of Products by Top 10 Routes of Administration, H1 2015 24 Number of Products by Stage and Top 10 Routes of Administration, H1 2015 25 Number of Products by Top 10 Molecule Types, H1 2015 26 Number of Products by Stage and Top 10 Molecule Types, H1 2015 27 Explore more reports on Neurology therapeutics at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/neurology-therapeutics . About Us: RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Kalinichev M.,Addex Therapeutics |
Rouillier M.,Addex Therapeutics |
Girard F.,Addex Therapeutics |
Royer-Urios I.,Addex Therapeutics |
And 10 more authors.
Journal of Pharmacology and Experimental Therapeutics | Year: 2013
Metabotropic glutamate receptor 7 (mGlu7) has been suggested to be a promising novel target for treatment of a range of disorders, including anxiety, post-traumatic stress disorder, depression, drug abuse, and schizophrenia. Here we characterized a potent and selective mGlu7 negative allosteric modulator (NAM) (1)-6-(2,4-dimethylphenyl)-2-ethyl-6,7- dihydrobenzo[d]oxazol- 4(5H)-one (ADX71743). In vitro, Schild plot analysis and reversibility tests at the target confirmed the NAM properties of the compound and attenuation of L-(1)-2-amino-4-phosphonobutyric acid-induced synaptic depression confirmed activity at the native receptor. The pharmacokinetic analysis of ADX71743 in mice and rats revealed that it is bioavailable after s.c. administration and is brain penetrant (cerebrospinal fluid concentration/ total plasma concentration ratio at Cmax 5 5.3%). In vivo, ADX71743 (50, 100, 150 mg/kg, s.c.) caused no impairment of locomotor activity in rats and mice or activity on rotarod in mice. ADX71743 had an anxiolytic-like profile in the marble burying and elevated plus maze tests, dose-dependently reducing the number of buried marbles and increasing open arm exploration, respectively. Whereas ADX71743 caused a small reduction in amphetamine-induced hyperactivity in mice, it was inactive in the mouse 2,5-dimethoxy-4-iodoamphetamine- induced head twitch and the rat conditioned avoidance response tests. In addition, the compound was inactive in the mouse forced swim test. These data suggest that ADX71743 is a suitable compound to help unravel the physiologic role of mGlu7 and to better understand its implication in central nervous system diseases. Our in vivo tests using ADX71743, reported here, suggest that pharmacological inhibition of mGlu7 is a valid approach for developing novel pharmacotherapies to treat anxiety disorders, but may not be suitable for treatment of depression or psychosis. © 2013 by The American Society for Pharmacology and Experimental Therapeutics.
Lavreysen H.,Janssen Research and Development |
Langlois X.,Janssen Research and Development |
Ahnaou A.,Janssen Research and Development |
Drinkenburg W.,Janssen Research and Development |
And 13 more authors.
Journal of Pharmacology and Experimental Therapeutics | Year: 2013
Modulation of the metabotropic glutamate type 2 (mGlu2) receptor is considered a promising target for the treatment of central nervous system diseases such as schizophrenia. Here, we describe the pharmacological properties of the novel mGlu2 receptor positive allosteric modulator (PAM) 3-cyano-1-cyclopropylmethyl- 4-(4-phenyl-piperidin-1-yl)-pyridine-2(1H)-one (JNJ-40068782) and its radioligand [3H]JNJ-40068782. In guanosine 5′-O-(3-[35S]thio)triphosphate binding, JNJ-40068782 produced a leftward and upward shift in the glutamate concentration-effect curve at human recombinant mGlu2 receptors. The EC50 of JNJ-40068782 for potentiation of an EC20-equivalent concentration of glutamate was 143 nM. Although JNJ-40068782 did not affect binding of the orthosteric antagonist [3H]2S-2-amino-2-(1S,2S-2-carboxycyclopropyl-1-yl)-3-(xanth-9- yl)propanoic acid (LY-341495), it did potentiate the binding of the agonist [3H](2S,2′R,3′R)-2-(2′,3′- dicarboxylcyclopropyl)glycine (DCGIV), demonstrating that it can allosterically affect binding at the agonist recognition site. The binding of [ 3H]JNJ-40068782 to human recombinant mGlu2 receptors in Chinese hamster ovary cells and rat brain receptors was saturable with a KD of ∼10 nM. In rat brain, the anatomic distribution of [3H]JNJ-40068782 was consistent with mGlu2 expression previously described and was most abundant in cortex and hippocampus. The ability of structurally unrelated PAMs to displace [3H]JNJ-40068782 suggests that PAMs may bind to common determinants within the same site. It is noteworthy that agonists also increased the binding affinity of [3H]JNJ-40068782. JNJ-40068782 influenced rat sleep-wake organization by decreasing rapid eye movement sleep with a lowest active dose of 3 mg/kg PO. In mice, JNJ-40068782 reversed phencyclidine-induced hyperlocomotion with an ED50 of 5.7 mg/kg s.c. Collectively, the present data demonstrate that JNJ-40068782 has utility in investigating the potential of mGlu2 modulation for the treatment of diseases characterized by disturbed glutamatergic signaling and highlight the value of [ 3H]JNJ-40068782 in exploring allosteric binding. Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics.